HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

Carlos Gómez-Martin,1 Elena Garralda,1 M José Echarri,2 Anabel Ballesteros,3 Alberto Arcediano,4 José Luis Rodríguez-Peralto,5 Manuel Hidalgo,1 Fernando López-Ríos6

ABSTRACT

Aim To study the HER2 gene amplification or overexpression in patients with advanced gastric cancer (GC) and their association with patient characteristics and patient survival.

Patients and methods Tumour tissue samples from 148 patients with advanced GC were studied for HER2 by immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH) and dual colour silver enhanced in situ hybridisation (dc-SISH) methods. Clinicopathological data from all patients were collected. Progression free survival and overall survival were also analysed.

Results Mean age was 67 (33–83) years; 75% were male subjects, and 51% had intestinal histological type. HER2+ rates were 10.1% (15/148) by IHC, 18.2% (27/148) by FISH+ or 21.6% (32/148) by dc-SISH+. There were significant differences in HER2+ rates according to histological type when FISH (intestinal, 23%; no intestinal, 4%; p<0.0001) or dc-SISH (intestinal, 26%; no intestinal, 6%; p<0.0001) amplification techniques were used. Median overall survival was significantly longer in HER2+ patients despite the determination technique used: IHC (21.4 vs 9.8 months, HR 0.42; p=0.005); FISH (19.6 vs 9.7 months, HR 0.49; p=0.007) or dc-SISH (19.6 vs 9.7 months, HR 0.53; p=0.009). Factors associated with favourable survival in the multivariate analysis were intestinal type and Her2+ determination by IHC, FISH or dc-SISH.

Conclusion HER2 gene amplification is significantly associated with patient survival. HER2 gene amplification approaches might be an optimal HER2/new testing strategy for the selection of HER2+ GC patients who are candidates to be treated with anti-HER2 therapies.

The prognostic value of HER2 in gastric cancer (GC) is controversial and historically its overexpression and/or amplification have been considered a poor prognosis factor. Nevertheless, recent studies appear to cast doubt on this negative view. A randomised phase III trial (ToGA) in advanced GC patients with 3+ HER2 (Human Epidermal growth factor Receptor type 2) overexpression measured by immunohistochemistry (IHC) or with HER2 amplification determined by fluorescence in situ hybridisation (FISH) has demonstrated that trastuzumab added to standard chemotherapy leads to a significant improvement in patients’ survival compared with chemotherapy alone, setting a new standard of treatment for these patients. The results of this trial have prompted the use of IHC test followed by FISH in IHC2+ cases for HER2 diagnostics. Dual colour silver enhanced in situ hybridisation (dc-SISH) is a new technique which combines the accuracy of the FISH technique and the morphological control of the IHC technique. In opposition to what has been stated by European Medicines Agency based on the ToGA subanalysis, in this paper we have shown how dc-SISH might be a better approach for the selection of HER2+ GC patients who are candidates to be treated with anti-HER2 therapies.

INTRODUCTION

GC is one of the most frequent tumours in the world with approximately 989 000 new cases and 738 000 deaths per year.1 In Spain, this tumour is currently the fifth leading cause of cancer-related death in both sexes.2 GC is often diagnosed at an advanced stage where curative radical gastrectomy is generally unfeasible and, consequently, survival rate for GC at 5 years of diagnosis is under 27%.3 Chemotherapy improves median overall survival (OS) for patients with unresectable and/or metastatic GC; however, no chemotherapy combination has been accepted as the gold standard.

Recently, a randomised phase III Trial in advanced GC patients (ToGA) with 3+ HER2 overexpression measured by IHC or with HER2 amplification determined by FISH has demonstrated that trastuzumab added to standard chemotherapy leads to a significant improvement in OS compared with chemotherapy alone, setting a new standard of treatment for these patients.4 It remains to be explained whether the longer survival rate achieved with standard chemotherapy in patients with HER2 overexpression and/or amplification is related to the presence of this molecular alteration by itself, the greater percentage of intestinal type cases among these patients or if it is due to factors as yet unknown.

In addition, the results of the ToGA study had prompted the use of IHC test followed by FISH in IHC2+ cases for HER2 diagnostics. Despite FISH being considered the gold standard for HER2 gene
amplification, a number of barriers such as the need of specialised equipment or the lack of morphological examination control prevent its wider use in the clinical setting. dc-SISH is a new technique which combines the accuracy of the FISH technique and the tissue histopathological features (morphological control) of the IHC technique. Our group has demonstrated the concordance between the FISH and dc-SISH techniques for determining HER2 gene amplification in GC samples.

The aims of this study were to determine the frequency of HER2 gene amplification by FISH and dc-SISH techniques and overexpression by IHC in patients with advanced GC, and to evaluate the association of HER2 gene amplification or overexpression with patient’s characteristics and survival, particularly in the subgroup of intestinal type cases.

MATERIALS AND METHODS

Patients’ eligibility
Tumour samples and medical records from patients who had been consecutively evaluated in our institutions for advanced GC treatment between January 2007 and December 2009 were retrospectively reviewed.

Eligibility criteria included patients with histologically confirmed advanced or/metastatic GC who had measurable and no measurable lesions by CT scan according to the Response Evaluation Criteria in Solid Tumours v1.014 who had not received previous treatment at the time of diagnosis. Patients had received treatment in line with the institution usual practice and data on tumour response had been assessed according to Response Evaluation Criteria in Solid Tumours criteria and recorded in the patient’s medical record. Tumour samples were obtained prior to any chemotherapy or systemic treatment.

The study was performed after approval by the Local Research Ethics Committee and in accordance with the Declaration of Helsinki, the Good Clinical Practices, and local ethical and legal requirements.

Study assessments
Clinical data were collected from medical records by a single clinician blinded to HER2 status, using a datasheet specifically developed for this study. Clinicopathological data such as gender, age, histological type according to the Lauren’s classification15 number and locations of metastases, previous surgery for GC and chemotherapy treatment received were reviewed.

Progression free survival (PFS), OS and clinical benefit rate (patients with either long lasting stabilisation of disease or objective partial or total response) were assessed from individual patient’s medical records. OS was measured from the date of diagnosis of metastatic disease until the date of death or last follow-up if alive. PFS was defined as the time from date of diagnosis of metastatic disease until first documentation of PD or death for any cause.

All H&E slides and paraffin blocks were centralised in a referral laboratory (Laboratorio de Dianas Terapeuticas). Two of the investigators (CGM, FLR) selected the most appropriate block and performed the interpretation of the different assays in a blinded manner to each other’s results. Also, 4 μm-thick sections were cut and placed on charged polylysine-coated slides.

To determine the frequency of HER2 gene amplification or overexpression in the tumour tissue samples the following assay methods were used: IHC, FISH and dc-SISH. The real-time PCR (RT-PCR) technique was used to study discordant cases. HER2+ disease (HER2+) was defined as IHC3+ or FISH+ (FISH ratio ≥2) or dc-SISH+ (dc-SISH ratio ≥2). Due to the retrospective nature of this study, none of the obtained results was used to modify the treatment of patients.

Immunohistochemistry
The HER2 protein status was determined by IHC using the Pathway anti-HER2/neu (4B5) antibody in the fully automated platform BenchMark ULTRA® (Ventana Medical Systems, Inc, Tucson, Arizona, USA). The slides were examined and scored independently by two experienced pathologists according to a previously defined score proposed by Ruschoff et al.16

Fluorescence in situ hybridisation
HER2 copy number was investigated by FISH using the PathVysion HER2 DNA probe kit (Vysis Inc, Abbot Laboratories, Illinois, USA) with the DAKO Histology FISH Accessory kit. The manufacturer’s instructions were modified using DAKO Histology kit in order to optimise the technique.17

Dual colour silver enhanced in situ hybridisation
Automated dc-SISH was performed on Ventana Benchmark XT (Ventana Medical Systems). INFORM HER2 DNA Probe and INFORM Chromosome 17 Probe were visualised on the same slide following manufacturer’s protocols with a few variations. Assay conditions were modified for optimal results. The entire assay procedure (deparaffinisation, pretreatment, hybridisation, stringency wash, signal detection and counterstaining) was fully automated.18

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>N = 148</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>67 ± 9.6</td>
</tr>
<tr>
<td>Range (min–max)</td>
<td>33–83</td>
</tr>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>111 (75)</td>
</tr>
<tr>
<td>Female</td>
<td>37 (25)</td>
</tr>
<tr>
<td><strong>Tumour sample origin, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Endoscopic biopsy from primary tumour</td>
<td>40 (27.0)</td>
</tr>
<tr>
<td>Surgical specimen from primary tumour</td>
<td>96 (64.8)</td>
</tr>
<tr>
<td>Surgical specimen from metastases</td>
<td>12 (8.1)</td>
</tr>
<tr>
<td><strong>First diagnosed with metastases, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>86 (58.1)</td>
</tr>
<tr>
<td>No</td>
<td>62 (41.9)</td>
</tr>
<tr>
<td><strong>Lauren’s histological type, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Intestinal</td>
<td>75 (50.7)</td>
</tr>
<tr>
<td>Diffuse</td>
<td>42 (28.3)</td>
</tr>
<tr>
<td>Undetermined</td>
<td>31 (20.9)</td>
</tr>
<tr>
<td><em><em>Localisation of the metastases</em>, n (%)</em>*</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>57 (38.5)</td>
</tr>
<tr>
<td>Lung</td>
<td>17 (11.5)</td>
</tr>
<tr>
<td>Thoracic lymph nodes</td>
<td>15 (10.1)</td>
</tr>
<tr>
<td>Abdominal lymph nodes</td>
<td>90 (60.8)</td>
</tr>
<tr>
<td>Peritoneal spread</td>
<td>48 (32.4)</td>
</tr>
<tr>
<td>Other (bone, ovarian, central nervous system)</td>
<td>14 (9.5)</td>
</tr>
<tr>
<td><strong>Treatment, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>121 (81.8)</td>
</tr>
<tr>
<td>Monotherapy</td>
<td>11 (7.4)</td>
</tr>
<tr>
<td>Platinum/fluoropyrimidines doublet</td>
<td>34 (23.0)</td>
</tr>
<tr>
<td>Platinum/taxane doublet</td>
<td>29 (19.6)</td>
</tr>
<tr>
<td>Other doublets</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>Platinum-based triplet</td>
<td>25 (16.9)</td>
</tr>
<tr>
<td>Trastuzumab + chemotherapy</td>
<td>20 (13.5)</td>
</tr>
<tr>
<td>Surgery</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>None</td>
<td>25 (16.9)</td>
</tr>
</tbody>
</table>

*Patients may have more than one location.
Resolution of discordant cases: RT-PCR
Tumours with discordant results obtained by FISH and dc-SISH and those with negative (0/1+) IHC and amplified by FISH or dc-SISH were analysed by RT-PCR using the LightMix kit HER2/neu (Roche Diagnostics, Penzberg, Germany). A 101 bp fragment of the HER2 gene and a 119 bp fragment of the RPL23 reference gene, both localised on chromosome 17q21, were amplified according to the manufacturer’s instructions.

A complete description of IHC, FISH, dc-SISH and RT-PCR, as well as procedures of the postanalytical phase, has been described elsewhere.13

Statistical analysis
The primary objective was to determine the frequency of HER2 gene amplification or overexpression in patients with advanced GC. Comparisons of the frequency of HER2 overexpression or amplification for different groups were performed using the Wilcoxon–Mann–Whitney test (for two groups) or the Kruskal–Wallis test (for more than two groups).

Secondary objectives were to evaluate the association of HER2 gene amplification or overexpression with patient’s characteristics and patient survival. For categorical variables, the possible association between the result of the technique used (IHC, FISH, dc-SISH) and the clinicopathological parameters was analysed using the Fisher’s exact test, $\chi^2$ test or Cochran–Mantel–Haenszel test (to compare one, two or more than two groups, respectively). Survival analyses (OS and PFS) according to HER2+ status were performed using the Kaplan–Meier method and differences between the patient groups were tested by the log-rank test. OS analyses were also performed according to the presence of intestinal versus no intestinal disease.

Multivariate survival analyses were determined using a Cox proportional hazards regression model for each of the HER2 variables together with clinical variables recognised as prognostic factors (peritoneal spread, non-intestinal type and presence of hepatic metastases) including risk ratios and 95% CI. A subgroup analysis based on tumour histology was also done. All tests were two sided, and $p$ values <0.05 were considered statistically significant. All statistical analyses were performed using SPSS V.15.0 for Windows (IBM SPSS Inc).

RESULTS
Patients’ characteristics
Complete clinicopathological information was obtained from medical records in 148 out of the 166 patients reviewed. All tumour samples were evaluated with all assays. Most patients (75%, n=111) were male subjects with a mean age of 67±9.6 years, ranging from 35 to 83 years.

Histological examinations from biopsies were obtained during an endoscopy in 40 (27.0%) patients and from surgical specimens in 108 (72.9%) patients of whom 12 (8.1%) were from distant metastases (eight peritoneal implants and four liver metastases). Histopathological diagnosis was intestinal type in 75 (50.7%) patients, diffuse type in 42 (28.3%) patients and undetermined type in 31 (20.9%) patients.

Most patients (81.8%, n=121) received chemotherapy, which was platinum-based in 42.6% (n=63). In 13.5% (n=20), trastuzumab was added to the chemotherapeutic regimen. Clinicopathological data are detailed in table 1.

Frequency of HER2 gene amplification or overexpression
Results from the HER2 overexpression by IHC analysis resulted in the following classification: 122 patients with score 0 (82.4%),

### Table 2 Clinicopathological correlation data

<table>
<thead>
<tr>
<th>Histology type (Lauren classification), n</th>
<th>IHC3+</th>
<th>IHC ≤2</th>
<th>FISH ratio ≥2</th>
<th>FISH ratio &lt;2</th>
<th>dc-SISH ratio ≥2</th>
<th>dc-SISH ratio &lt;2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intestinal (%) 75 (50.7)</td>
<td>11</td>
<td>64</td>
<td>23</td>
<td>52</td>
<td>26</td>
<td>49</td>
</tr>
<tr>
<td>No intestinal (%) 73 (49.3)</td>
<td>4</td>
<td>69</td>
<td>4</td>
<td>60</td>
<td>5</td>
<td>67</td>
</tr>
<tr>
<td>p Value*</td>
<td>0.0641</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Site of metastases, n

<table>
<thead>
<tr>
<th>Site of metastases, n</th>
<th>Liver</th>
<th>Lung</th>
<th>Bone</th>
<th>Peritoneal</th>
</tr>
</thead>
<tbody>
<tr>
<td>p Value*</td>
<td>0.2694</td>
<td>0.1848</td>
<td>0.6171</td>
<td>0.0604</td>
</tr>
<tr>
<td></td>
<td>0.1152</td>
<td>0.1987</td>
<td>0.3516</td>
<td>0.0876</td>
</tr>
<tr>
<td></td>
<td>0.0550</td>
<td>0.0564</td>
<td>0.2018</td>
<td>0.0218</td>
</tr>
</tbody>
</table>

*P Value according to $\chi^2$ test.

dc-SISH, dual colour silver enhanced in situ hybridisation; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry.

### Table 3 Progression free survival and overall survival according to HER2 overexpression/HER2 amplification results

<table>
<thead>
<tr>
<th></th>
<th>IHC3+</th>
<th>IHC ≤2</th>
<th>FISH ratio ≥2</th>
<th>FISH ratio &lt;2</th>
<th>dc-SISH ratio ≥2</th>
<th>dc-SISH ratio &lt;2</th>
</tr>
</thead>
<tbody>
<tr>
<td>med PFS (months)</td>
<td>7.98</td>
<td>5.45</td>
<td>7.98</td>
<td>5.35</td>
<td>7.98</td>
<td>5.35</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.62 (0.34 to 1.13)</td>
<td>0.58 (0.36 to 0.94)</td>
<td>0.61 (0.39 to 0.95)</td>
<td>0.029</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p Value</td>
<td>0.119</td>
<td>0.027</td>
<td>0.81</td>
<td>0.029</td>
<td></td>
<td></td>
</tr>
<tr>
<td>med OS (months)</td>
<td>21.29</td>
<td>9.82</td>
<td>19.59</td>
<td>9.66</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.42 (0.21 to 0.84)</td>
<td>0.49 (0.29 to 0.83)</td>
<td>0.53 (0.33 to 0.85)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p Value</td>
<td>0.005</td>
<td>0.007</td>
<td>0.009</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*dc-SISH, dual colour silver enhanced in situ hybridisation; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; med PFS, median progression free survival; med OS, median overall survival.
Figure 1  Overall survival according to HER2 overexpression by immunohistochemistry (IHC) (A), HER2 gene amplification by fluorescence in situ hybridisation (FISH) (B) or dual colour silver enhanced in situ hybridisation (SISH) (C) techniques.

- Five patients with score 1+ (3.4%), six with score 2+ (4.1%) and 15 with score 3+ (10.1%), with this last category being considered the IHC+ group.

- HER2 amplification by FISH obtained 27 cases of HER2 oncogen amplification. Mean ratio of HER2 to CEP17 was 5.81 (95% CI 4.64 to 6.98) and range 2.1–12.3. HER2 amplification
Clinical correlation with HER2 gene amplification or overexpression

There were no statistically significant differences in HER2 overexpression by IHC results according to sex, age or metastatic site. Likewise, no statistically significant differences were observed in HER2 amplification results obtained by FISH or dc-SISH according to age and sex. However, according to metastatic site a lower incidence of amplified results was obtained for patients with peritoneal carcinomatosis when dc-SISH technique was used, and this difference was statistically significant (p=0.0218) (table 2).

All the three techniques used were highly positive for the intestinal histological type: 73.3% of cases with IHC overexpression, 85.1% cases with FISH amplification and 81.25% of cases amplified by dc-SISH corresponding to the intestinal type. However, a statistically significant association was found only between the presence of intestinal type and a positive result in the FISH or dc-SISH amplification techniques (p<0.0001) (table 2).

Discordant cases

Samples amplified by FISH and dc-SISH, considered as a positive control for HER2 gene amplification, were all found to be amplified using the RT-PCR quantitative approach. Similarly, samples assessed as negative for HER2 gene amplification by both FISH and dc-SISH gave a normalised ratio of HER2 to RPL19 of 1 to 1 (range from 0.836 to 1.0) which is below the cut-off limit of 2 and confirms the absence of amplification. No amplification by FISH was observed in six out of the 34 cases amplified by dc-SISH (cases 8, 39, 67, 68, 113 and 129). The dc-SISH amplification ratio was between 2 and 3 and all of them were IHC 0/1 +. All these cases were polysomic and were confirmed as negative for amplification by RT-PCR.

In five cases, the IHC result was 0/1+ despite amplification either by FISH or by dc-SISH techniques. In three of these five cases there was no remaining tissue to perform an appropriate RT-PCR analysis. For the last two cases the result of RT-PCR confirmed the HER2/new amplification shown by FISH and dc-SISH tests.

Patient survival correlation with HER2 gene amplification or overexpression

Median PFS was 6.14 months (95% CI 5.19 to 7.23 months) and median OS was 11.37 months (95% CI 9.00 to 13.83 months) for the entire population.

No differences were observed in PFS according to HER2 overexpression, although a statistically significant difference was observed when groups were analysed according to the presence or amplification assessed by FISH or dc-SISH (table 5).

Mean OS was significantly longer in the group of patients with HER2 overexpression or amplification, whatever the technique used for its determination: IHC (21.4 vs 9.8 months, HR 0.42; p=0.005), FISH (19.6 vs 9.7 months, HR 0.49; p=0.007) or dc-SISH (19.6 vs 9.7 months, HR 0.55; p=0.009) (table 5; figure 1).

Median OS for the subgroup of patients with intestinal type GC (14.3 months; 95% CI 12.02 to 21.16) was significantly higher to that observed in the no intestinal group (7.56 months, 95% CI 6.24 to 10.31) (log-rank p=0.0011).

Multivariate survival analyses

For the entire patient population, the presence of peritoneal carcinomatosis was found to be a negative prognostic factor for OS (HR: 1.60; 95% CI 1.08 to 2.38; p=0.020), while the presence of intestinal histological type (intestinal vs no intestinal: HR: 0.68; 95% CI 0.46 to 0.99; p=0.044), the HER2 protein overexpression assessed by IHC (IHC3+ vs IHC ≤2: HR: 0.47; 95% CI 0.24 to 0.94; p=0.032), or the HER2 gene amplification by FISH (ratio ≥2 vs ratio <2: HR: 0.58; 95% CI 0.34 to 0.99; p=0.046) or by dc-SISH (ratio ≥2 vs ratio <2: HR: 0.58; 95% CI 0.36 to 0.95; p=0.023) was found to be a favourable prognostic factor.

The same analysis was performed for the subgroup of patients with intestinal type. In this case, no prognostic value for HER2 protein overexpression or for its amplification determined by FISH was observed. Only the presence of hepatic metastases by dc-SISH was observed in 32 cases, with a mean ratio of 6.87 (95% CI 5.51 to 8.23) and range 2.1–16.7.

Figure 2. Overall survival according to Lauren’s histological type of carcinoma with or without HER2 gene amplification by dual colour silver enhanced in situ hybridisation.

Table 2. Median PFS and OS according to the presence of peritoneal carcinomatosis and intestinal histological type (a) and HER2 protein overexpression and amplification (b).

Table 3. Multivariate survival analyses for OS (HR and 95% CI).

Table 4. Survival data according to Lauren’s histological type (a) and HER2 protein overexpression and amplification (b).
(HR: 1.74; 95% CI 1.03 to 2.94; p=0.058) or peritoneal carcinomatosis (HR: 2.87; 95% CI 1.56 to 5.30; p=0.0007) was statistically significant.

When OS was analysed using a Kaplan–Meier model and stratifying patients according to both their Lauren’s histological type and positive or negative result of IHC or ISH tests, only dc-SISH was able to find significant differences between the four subgroups of patients (p=0.0003, log-rank test). The Cox regression analysis model showed similar results (p=0.0005) (figure 2).

DISCUSSION

Results of the clinicopathological correlation with HER2 status in our series are similar to those described in previous studies, with a high correlation with the presence of the intestinal histological type, particularly when HER2 amplification techniques were used.19 20

On univariate analysis, median OS was significantly longer in HER2+ patients, despite the determination technique used, and this prognostic value was confirmed in the multivariate survival analyses when dc-SISH was used. These findings corroborate phase III ToGA study7 results, wherein the significant improvement in the mean OS observed with the addition of trastuzumab to chemotherapy in patients with HER2+ metastatic GC was mainly the result of the survival advantage conferred to patients with high expression of the HER2 protein and/or confirmed HER2 amplification by FISH. Noteworthy, in the three HER2 determination techniques used the mean OS rates in HER2+ patients in our study almost doubled those achieved in HER2 patients.

For the whole population, HER2 positivity and the intestinal type were found to be factors associated with a more favourable survival in advanced GC patients in the multivariate survival analyses. The same conclusion was reached in a US and European collaborative analysis recently presented by Shah et al at the ASCO 2011 meeting.10 However, in the subgroup analysis based on tumour histology and HER2 status, only HER2 amplification determined by means of dc-SISH was deemed to be of prognostic value for intestinal type patients.

In addition, the presence of peritoneal carcinomatosis was found to be a negative prognostic factor for OS in the whole group of patients or when analysing only the subgroup of intestinal patients.

Despite not being a randomised study (which can be considered a potential weakness of our trial) patients were not selected but were included consecutively as soon as they were referred for assessment; this fact diminishes the possible selection bias.

The three diagnostic techniques used (IHC, FISH and dc-SISH) have demonstrated to be comparable for HER2 status assessment.13 Only a low percentage of discordant cases were observed between FISH and dc-SISH or between IHC and FISH, which were resolved by quantitative RT-PCR.

Even if the three techniques were similar for assessing the subgroup of patients with favourable prognosis, only 10% of HER2+ cases were detected by IHC compared with 18%–22% of HER2+ cases detected by hybridisation techniques. In addition, there is a minor subjectivity in the interpretation of results with the hybridisation techniques compared with the IHC method, for which three different criteria have been developed in the last 3 years.15 21 22 Hybridisation techniques are less time-dependent (signal permanency) and easier to be reproduced interlaboratory and intralaboratory, particularly with the bright-field microscopic technique adopted in the dc-SISH method, which have been validated by our group.13

In view of all these advantages, and in opposition to what has been stated by European Medicines Agency based on the ToGA subanalysis, we consider that the hybridisation techniques in general, and dc-SISH in particular, might be a better approach for the selection of HER2+ GC patients who are candidates to be treated with anti-HER2 therapies. Interestingly, a similar conclusion has been reached in breast carcinomas and proposed in gastric carcinoma, given the inconsistencies in HER2 IHC testing.23–24 In this regard, a comprehensive analysis of some of the ToGA subgroups would be most valuable in providing robust guidelines for HER2 testing.

REFERENCES


HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

Carlos Gómez-Martín, Elena Garralda, M José Echarri, Anabel Ballesteros, Alberto Arcediano, José Luis Rodríguez-Peralto, Manuel Hidalgo and Fernando López-Ríos

*J Clin Pathol* 2012 65: 751-757 originally published online May 8, 2012
doi: 10.1136/jclinpath-2012-200774

Updated information and services can be found at: [http://jcp.bmj.com/content/65/8/751](http://jcp.bmj.com/content/65/8/751)

These include:

**References**

This article cites 20 articles, 5 of which you can access for free at: [http://jcp.bmj.com/content/65/8/751#BIBL](http://jcp.bmj.com/content/65/8/751#BIBL)

**Open Access**

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: [http://creativecommons.org/licenses/by-nc/3.0/](http://creativecommons.org/licenses/by-nc/3.0/) and [http://creativecommons.org/licenses/by-nc/3.0/legalcode](http://creativecommons.org/licenses/by-nc/3.0/legalcode)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Open access (113)
- Molecular genetics (355)
- Pancreatic cancer (121)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)